Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia
Status:
TERMINATED
Trial end date:
2024-12-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the feasibility and safety of injectable naltrexone (NTX;380 mg) in conjunction with oral bupropion (BUP; 450 mg daily)NTX-BUP administration among individuals with schizophrenia spectrum disorders that smoke cigarettes and to evaluate change on smoking-related measures and symptoms of schizophrenia.
Phase:
PHASE1
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston